机译:以PML为靶标可消除静止期白血病引发细胞
Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology,Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10021, USA Department of Pathology, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10021, USA;
Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology,Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10021, USA Department of Pathology, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10021, USA;
Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology,Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10021, USA Department of Pathology, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10021, USA;
Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo 160-8582, Japan;
Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin 10043, Italy;
Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo 160-8582, Japan;
Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA;
Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA;
Department of Pathology, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10021, USA;
Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology,Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10021, USA Department of Pathology, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10021, USA;
机译:通过靶向PML / RARA消除急性早幼粒细胞白血病起始细胞。
机译:通过靶向PML / RARA消除急性早幼粒细胞白血病起始细胞
机译:BCL-2抑制作用靶向氧化磷酸化并选择性根除静止的人类白血病干细胞
机译:肝癌,肝窦和外周血中静止的CD8 + T细胞的基因表达和途径分析-毒物基因组学和预防靶标研究
机译:处于静止状态的自噬诱导:静止细胞中细胞自相残杀的体外和体内表征。
机译:以PML为靶标可消除静止期白血病引发细胞
机译:BCL-2抑制靶向氧化磷酸化并选择性消除静态人类白血病干细胞。
机译:靶向根除工程间充质干细胞介导的前列腺癌